GLAXOSMITHKLINE PLC Form 6-K January 11, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 11 January 2019

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc(the'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status Chief Executive Officerc) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

². platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

b) Nature of the transaction Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares

£15.2440

Price

e) Date of the transaction 2019-01-10

Place of the transaction

f) London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status President, Global Vaccines

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence each

('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares

Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

b) Nature of the transaction

Aggregated volume
16 Ordinary Shares

Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics & Compliance

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793
Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares

Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Miels

b) Position/status President, Global Pharmaceuticals

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordin

Ordinary shares of 25 pence each

('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares
b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares

Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name
 b) Position/status
 c) Initial notification/amendment
 Mr D S Redfern
 Chief Strategy Officer
 Initial notification

Details of the issuer, emission allowance market participant, auction

². platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) 16 Ordinary Shares

Aggregated volume £15.2440

Price

Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R Simard

b) Position/status President, Pharma Supply Chain

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

² platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares

Price £15.2440

Price

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/statusc) Initial notification/amendmentd) SVP, Human Resourcese) Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

b) Nature of the transaction

ISIN: GB0009252882

Acquisition of Ordinary Shares

under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) Aggregated volume 16 Ordinary Shares

Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status President, Global Affairs

c) Initial notification/amendment Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place

where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

d) 16 Ordinary Shares

Aggregated volume £15.2440

Price

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name
 b) Position/status
 c) Initial notification/amendment
 Mrs V A Whyte
 Company Secretary
 Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary Shares

b) Nature of the transaction under the Company's Share

Reward Plan.

Price(s) Volume(s)

c) Price(s) and volume(s) £15.2440 8 (partnership shares)

£15.2440 8 (matching shares)

Aggregated information

Aggregated volume 16 Ordinary Shares

Price £15.2440

e) Date of the transaction 2019-01-10

f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: January 11, 2019

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc